MedTrace Logo

CCR5-blockade in Metastatic Colorectal Cancer

NCT01736813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2017-03-22

No results posted yet for this study

Summary

The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth. The agent for the inhibition of CCR5 has already received FDA approval for treatment of HIV and has shown little side effects and toxicities even on long term treatment. Therefore CCR5-inhibition has the potential of providing non-toxic tumor growth inhibition.

Conditions

Interventions

DRUG

Maraviroc

Twelve patients with 300 mg/bid

Sponsors & Collaborators

  • University Hospital Heidelberg

    collaborator OTHER

  • National Center for Tumor Diseases, Heidelberg

    lead OTHER

Principal Investigators

  • Niels Halama, MD · National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany

  • Dirk Jaeger, MD · National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-12-31
Completion
2014-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736813 on ClinicalTrials.gov